Paari Murugan, MD

Dr. Murugan is a board certified anatomic pathologist whose area of expertise is in the surgical pathology of genitourinary and bone / soft tissue tumors. He works closely with multidisciplinary teams involving urologists, orthopedicians, medical/radiation oncologists, and radiologists in providing expert care to patients with kidney, urinary bIadder, prostate, adrenal, testis, bone and soft tissue neoplasms. His role involves establishing accurate tissue diagnosis on biopsies and surgical excisions, a critical component in guiding treatment decisions. 

In addition to the clinical diagnostic role, Dr. Murugan is involved in medical student, resident and fellow education as well as translational research. He enjoys teaching and is constantly engaged with residents and fellows with interactive discussions during daily sign-outs and conferences. In acknowledgment of his contribution, he was conferred the Anatomic Pathology Teacher of the Year award in 2015 and 2018. His research projects mainly focus on the histomorphological features of neoplastic entities and their immunohistochemical and molecular profiles. He correlates these findings with tumor behavior in relevance to therapy and prognosis. 

Dr. Murugan has over 40 peer-reviewed publications, 23 scientific meeting presentations and is currently working on several projects including studies addressing bladder cancer biomarkers, an innovative model for processing prostate biopsies, low grade prostate cancer in African-American men and clinical markers of heterocyclic aromatic amines for human biomonitoring. He serves as Medical Director of the University of Minnesota CTSI's Biorepository and Laboratory Services and as peer-reviewer for several journals including Journal of Urology, BMC Cancer, Virchows Archiv and Human Pathology.

Selected Publications

PubMed link

• Umbreen S, Banday M, Jamroze A, Ganaie A, Ferrari M, Murugan P, Morrissey C, Corey E, Konety BR, and Saleem M. COMMD3:BMI1 fusion and COMMD3 protein regulate C-MYC transcription and metastasis: Clinically relevant therapeutic target for metastatic prostate cancer. Mol Cancer Ther. 2019 Aug 29. pii: molcanther.0150.2019. doi: 10.1158/1535-7163.MCT-19-015
• Dianat S, Yousaf H, Murugan P, Marette S. Pseudomyogenic hemangioendothelioma-A case report and review of the literature. Radiol Case Rep. 2019 Oct;14(10):1228-1232. doi: 10.1016/j.radcr.2019.06.029
• Chen H, Krishnamachari S, Guo J, Yao L, Murugan P, Weight CJ, Turesky RJ. Quantitation of Lipid Peroxidation Product DNA Adducts in Human Prostate by Tandem Mass Spectrometry: A Method That Mitigates Artifacts. Chem Res Toxicol. 2019 Sep 16;32(9):1850-1862. doi: 10.1021/acs.chemrestox.9b00181
• Umbreen S, Banday MM, Jamroze A, Mansini AP, Ganaie AA, Ferrari MG, Maqbool R, Beigh FH, Murugan P, Morrissey C, Corey E, Konety BR, Saleem M. COMMD3:BMI1 fusion and COMMD3 protein regulate C-MYC transcription: Novel therapeutic target for metastatic prostate cancer. Mol Cancer Ther. 2019 Aug 29;. doi: 10.1158/1535-7163.MCT-19-0150
• Murugan P, Shukla D, Morocho J, Smith D, Sciacca D, Pickard M, Wahlsten M, Gunderson A, Konety B, Khalifa MA, Warlick C. Prostate Biopsy Processing. Am J Clin Pathol. 2019 Aug 21;. doi: 10.1093/ajcp/aqz101
• Khalifa MA, Atri M, Klein ME, Ghatak S, Murugan P. Adenomyosis As a Confounder to Accurate Endometrial Cancer Staging. Semin Ultrasound CT MR. 2019 Aug;40(4):358-363. doi: 10.1053/j.sult.2019.04.004. Epub 2019 Apr 18. Review.
• Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558
• Narayan VM, Gupta S, Davicioni E, Murugan P, Gibb EA, Konety B. Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. Clin Genitourin Cancer. 2019 May 25;. doi: 10.1016/j.clgc.2019.05.019
• Sathianathen NJ, Warlick CA, Soubra A, Balaji P, Metzger GJ, Spilseth B, Murugan P, Ordonez M, Weight CJ, Konety BR. Difference in MRI-guided biopsy cancer detection rates between individual clinicians. Urol Oncol. 2019 May;37(5):299.e1-299.e6. doi: 10.1016/j.urolonc.2019.01.032.
• Sathianathen NJ, Warlick CA, Weight CJ, Ordonez MA, Spilseth B, Metzger GJ, Murugan P, Konety BR. A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy. BJU Int. 2019 Apr;123(4):612-617. doi: 10.1111/bju.14617
• Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039
• Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple KG, Paner GP, Patel MI, Raspollini MR, Lopez-Beltran A, Konety BR. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol. 2019 Jan;37(1):107-114. doi: 10.1007/s00345-018-2421-5
• Savani M, Murugan P, Skubitz KM. Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure. Clin Sarcoma Res. 2019;9:1. Published 2019 Jan 15. doi:10.1186/s13569-018-0111-0
• Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, Hunt MA, Lou E, Miller JS. Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer. 2018 Jun 19;6(1):58. doi: 10.1186/s40425-018-0357-3. PubMed PMID: 29914578.
• Rosenberg JE, Albersheim JA, Sathianathen NJ, Murugan P, Weight CJ. Five new cases of primary renal carcinoid tumor: Case reports and literature review.Pathol Oncol Res. 2018 Oct 25.
• Alanee, S, Alvarado-Cabrero, I, Murugan, P, Kumar, R, Nepple, KG, Paner, GP, Patel, MI, Raspollini, MR, Lopez-Beltran, A & Konety, Update of the International Consultation on Urological Diseases on bladder cancer 2018: Non-urothelial cancers of the urinary bladder. World Journal of Urology. 2018 Aug 1. DOI: 10.1007/s00345-018-2421-5 
• Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill E, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie HA, Iyer G, Bochner BH, Coleman J, Solit DB. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res. 2018 Oct 23.
• Bellamri M, Xiao S, Murugan P, Weight CJ, Turesky RJ. Metabolic Activation of the Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine in Human Prostate. Toxicol Sci. 2018 Jun 1;163(2):543-556. doi: 10.1093/toxsci/kfy060. PubMed PMID: 29596660; PubMed Central PMCID: PMC5974788.
• Glumac PM, Forster CL, Zhou H, Murugan P, Gupta S, LeBeau AM. The identification of a novel antibody for CD133 using human antibody phage display. Prostate. 2018 May 22. doi: 10.1002/pros.23656. [Epub ahead of print] PubMed PMID: 29790189.
• Qiu K, Zhao Z, Haghiashtiani G, Guo SZ, He M, Su R, Zhu Z, Bhuiyan DB, Murugan P, Meng F, Park SH, Chu CC, Ogle BM, Saltzman DA, Konety BR, Sweet RM, McAlpine MC. 3D Printed Organ Models with Physical Properties of Tissue and Integrated Sensors. Adv Mater Technol. 2018 Mar;3(3). pii: 1700235. doi: 10.1002/admt.201700235. Epub 2017 Dec 6. PubMed PMID: 29608202; PubMed Central PMCID: PMC5877482.
• Stein T, Murugan P, Li F, El Hag MI. Can Medullary Thyroid Carcinoma Arise in Thyroglossal Duct Cysts? A Search for Parafollicular C-cells in 41 Resected Cases. Head Neck Pathol. 2018 Mar;12(1):71-74. doi: 10.1007/s12105-017-0826-x. Epub 2017 May 23. PubMed PMID: 28536894; PubMed Central PMCID: PMC5873481.
• Murugan P, Rao P, Tamboli P, Czerniak B, Guo CC. Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Pathol Oncol Res. 2018 Jan;24(1):153-159. doi: 10.1007/s12253-017-0228-0. Epub 2017 Apr 20. PubMed PMID: 28429277.
• Yun BH, Xiao S, Yao L, Krishnamachari S, Rosenquist TA, Dickman KG, Grollman AP, Murugan P, Weight CJ, Turesky RJ. A Rapid Throughput Method To Extract DNA from Formalin-Fixed Paraffin-Embedded Tissues for Biomonitoring Carcinogenic DNA Adducts. Chem Res Toxicol. 2017 Dec 18;30(12):2130-2139. doi: 10.1021/acs.chemrestox.7b00218. Epub 2017 Nov 27. PubMed PMID: 29120619; PubMed Central PMCID: PMC5822421.
• Shahi M, Dolan M, Murugan P. Hyalinizing Clear Cell Carcinoma of the Bronchus. Head Neck Pathol. 2017 Dec;11(4):575-579. doi: 10.1007/s12105-017-0820-3. Epub 2017 May 16. PubMed PMID: 28508996; PubMed Central PMCID: PMC5677074.
• Mesa H, Gilles S, Datta MW, Murugan P, Larson W, Dachel S, Manivel JC. Comparative immunomorphology of testicular Sertoli and sertoliform tumors. Hum Pathol. 2017 Mar;61:181-189. doi: 10.1016/j.humpath.2016.11.004. Epub 2016 Dec 8. PubMed PMID: 27939779.
• Xiao S, Guo J, Yun BH, Villalta PW, Krishna S, Tejpaul R, Murugan P, Weight CJ, Turesky RJ. Biomonitoring DNA Adducts of Cooked Meat Carcinogens in Human Prostate by Nano Liquid Chromatography-High Resolution Tandem Mass Spectrometry: Identification of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine DNA Adduct. Anal Chem. 2016 Dec 20;88(24):12508-12515. doi: 10.1021/acs.analchem.6b04157. Epub 2016 Dec 1. PubMed PMID: 28139123; PubMed Central PMCID: PMC5545982.
• Mesa H, Gilles S, Datta MW, Murugan P, Larson W, Dachel S, Manivel C. Immunophenotypic differences between neoplastic and non-neoplastic androgen-producing cells containing and lacking Reinke crystals. Virchows Arch. 2016 Dec;469(6):679-686. Epub 2016 Oct 1. PubMed PMID: 27696245.
• Murugan P. Editorial Comment. J Urol. 2016 Apr;195(4 Pt 1):891-2. doi: 10.1016/j.juro.2015.10.184. Epub 2016 Jan 8. PubMed PMID: 26777242.
• Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct;33(10):427.e17-23. doi: 10.1016/j.urolonc.2015.04.011. Epub 2015 May 23. PubMed PMID: 26004164; PubMed Central PMCID: PMC4584175.
• Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep;28(9):1225-35. doi: 10.1038/modpathol.2015.68. Epub 2015 Jun 26. PubMed PMID: 26111976.
• Murugan P, Stevenson ME, Hassell LA. Performance validation in anatomic pathology: successful integration of a new classification system into the practice setting using the updated lung non-small cell carcinoma recommendations. Arch Pathol Lab Med. 2014 Jan;138(1):105-9. doi: 10.5858/arpa.2012-0750-OA. PubMed PMID: 24377817.

Books

• Murugan P, Alanee S. Squamous Carcinoma of Bladder: In Bladder Cancer, International Consultation on Bladder Cancer, European Association of Urology, 3rd ed. 2017
• Gopal M, Murugan P, Mamdani N, Jayashree S, Gopichandran V: Acing the USMLE and the Match – A guide for international medical graduates. Jaypee Medical Publishers, New Delhi, 2008.